Ascendis Pharma A/S
Ascendis Pharma A/S (ASND) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
asnd · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Ascendis Pharma A/S (ASND) measures how much investors pay for each dollar of the company's trailing earnings. ASND's current PE ratio of 21.89x is calculated by dividing its stock price of $208.41 by its TTM earnings per share of $8.21. −72.6% discount vs 5Y avg 79.8x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2011 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Ascendis Pharma A/SYou ASND | $12.9B | 21.89x | -8.4% | $8.21 |
 BridgeBio Pharma, Inc. BBIO | $13.2B | N/A | — | -$3.70 |
 BioMarin Pharmaceutical Inc. BMRN | $10.8B | 32.67x | +36.7% | $1.82 |
 Exelixis, Inc. EXEL | $13.2B | 15.12x | -36.7% | $2.88 |
 Guardant Health, Inc. GH | $16.9B | N/A | — | -$3.32 |
 Ionis Pharmaceuticals, Inc. IONS | $12.1B | N/A | — | -$2.38 |
 Madrigal Pharmaceuticals, Inc. MDGL | $11.1B | N/A | — | -$12.85 |
Industry Average 2 peers with valid PE | — | 23.90x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-3.61 | — | |
2024-12-31 FY2024 | — | $-6.53 | — | |
2023-12-31 FY2023 | — | $-8.55 | — | |
2022-12-31 FY2022 | — | $-10.40 | — | |
2021-12-31 FY2021 | — | $-7.00 | — | |
2020-12-31 FY2020 | — | $-8.28 | — | |
2019-12-31 FY2019 | — | $-4.69 | — | |
2018-12-31 FY2018 | — | $-3.17 | — | |
2017-12-31 FY2017 | — | $-3.68 | — | |
2016-12-31 FY2016 | — | $-2.58 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Ascendis Pharma A/S (ASND) measures how much investors pay for each dollar of the company's trailing earnings. ASND's current PE ratio of 21.89x is calculated by dividing its stock price of $208.41 by its TTM earnings per share of $8.21.
Frequently asked questions
ASND pe ratio · 6 questionsASND's current PE ratio is 21.89x as of 2026-06-08, based on a stock price of $208.41 and TTM EPS of $8.21. Data sourced from Financial Modeling Prep via ASND's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Ascendis Pharma A/S SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08